Walmart Employee Benefits Add Free GLP-1 Drugs

The largest private employer in the United States is making a bold bet on employee healthcare. Walmart announced on October 13, 2026, that it will cover more than 250 prescription medications at no cost to its employees starting in 2027, including high-profile GLP-1 drugs like Ozempic and Mounjaro for workers with Type 2 diabetes.

A Landmark Move in Corporate Health Benefits

Walmart’s decision comes at a time when many major U.S. employers are scaling back healthcare benefits to manage rising medical costs. The retail giant is moving in the opposite direction, expanding coverage even as competitors eliminate GLP-1 coverage for weight loss. Chief People Officer Donna Morris outlined the changes in a memo to the company’s approximately 1.6 million U.S. workers, framing the expansion as part of a multi-year strategy to improve associate wellbeing and retention.

The announcement arrives just weeks before Walmart’s open enrollment period closes on November 6, 2026, giving employees a compelling reason to engage with their benefits options. For a company that once faced widespread criticism over its pay and benefits practices, the move signals a continued evolution in how corporate America’s largest employers approach workforce healthcare.

What Is Covered Under the New Plan

The expanded prescription drug list includes more than 250 medications spanning several critical categories:

• GLP-1 medications: Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro will be available at no cost for employees with Type 2 diabetes, following a prior authorization process.
• Insulin products: Multiple insulin formulations will be covered without charge for employees on the company’s medical plans.
• Inhalers: Prescription inhalers for respiratory conditions are included in the no-cost formulary.
• Other medications: Treatments for migraines, dementia, and cardiovascular conditions round out the expanded list.

It is important to note that Walmart is not covering GLP-1 drugs for weight loss purposes. The coverage applies specifically to employees diagnosed with Type 2 diabetes who receive prior authorization. This distinction aligns with a broader industry trend where employers are narrowing GLP-1 coverage to therapeutic uses rather than cosmetic or lifestyle applications.

Specialist Access and Rare Disease Support

Beyond prescription drugs, Walmart is expanding an existing program that connects employees with top-tier medical specialists. The company already covers specialist consultations at the Mayo Clinic and Cleveland Clinic for cancer patients. Starting in 2027, that benefit extends to employees being evaluated for or diagnosed with rare neurological conditions, including:

• Amyotrophic lateral sclerosis (ALS)
• Multiple sclerosis
• Parkinson’s disease

Employees under most medical plans will be eligible for second opinions from specialists at these renowned institutions. This expansion reflects a growing recognition that early access to expert diagnosis can dramatically improve outcomes for rare diseases, where misdiagnosis rates are historically high.

Premium Increases Kept Minimal

One of the most notable aspects of Walmart’s announcement is the company’s effort to keep premium increases modest. Starting health insurance premiums will rise by just $1.50 per biweekly pay period, bringing the starting plan to $39.80. Walmart confirmed this increase is smaller than the adjustment made in 2026, a feat the company attributes to years of planning and testing.

In contrast, many U.S. employers are implementing double-digit percentage increases in healthcare contributions from workers. The Kaiser Family Foundation has reported that average annual family premiums rose approximately 7 percent in 2026, outpacing both wage growth and inflation. Walmart’s ability to expand benefits while limiting premium growth is a product of its massive scale and long-term benefits strategy.

Neatal Intensive Care Leave Added

Walmart is also introducing up to 12 weeks of neonatal intensive care unit (NICU) leave for parents, which can be taken in addition to existing parental and maternity leave. This benefit addresses a gap in corporate family leave policies, as NICU stays are often unplanned and can last weeks or months, placing enormous stress on working parents.

The NICU leave addition complements Walmart’s existing family benefits, which include approximately $20,000 in financial assistance for fertility treatments, adoption, or surrogacy services, and 20 no-cost therapy sessions annually per employee.

The Broader Corporate Healthcare Landscape

Walmart’s announcement stands out against a backdrop of corporate healthcare contraction. Several major employers have eliminated or reduced GLP-1 coverage in recent months, citing costs that can exceed $1,000 per month per employee. The trend has sparked debate about whether employers have an obligation to cover breakthrough medications that could prevent more expensive complications down the line.

By covering GLP-1 drugs for diabetes management, Walmart is betting that upfront investment in medication access will reduce long-term healthcare spending through fewer complications, hospitalizations, and emergency interventions. This approach aligns with value-based care principles that are gaining traction among large self-insured employers.

The decision also reinforces Walmart’s competitive positioning in the labor market. With 1.6 million U.S. employees, the company operates in a sector where turnover is high and benefits packages are increasingly differentiated. Offering no-cost access to medications that millions of Americans struggle to afford gives Walmart a tangible advantage in recruitment and retention.

What This Means for the Future of Employer Benefits

Walmart’s move may pressure other large employers to reconsider their approach to prescription drug coverage, particularly for high-cost specialty medications. If the retailer’s strategy demonstrates measurable returns in employee health outcomes and retention metrics, it could shift industry benchmarks.

For employees, the expansion represents a meaningful reduction in out-of-pocket healthcare costs at a time when medical expenses are a leading source of financial stress for American households. The inclusion of GLP-1 drugs, even limited to diabetes, sends a signal that breakthrough medications can be made accessible through employer-sponsored plans without breaking the budget.

As open enrollment season continues through November 6, Walmart employees will have the opportunity to review and select from the enhanced benefit options. The company has indicated that these changes reflect the culmination of years of planning rather than a one-time response to market pressures, suggesting that further expansions may be on the horizon.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous